Post

Touchlight and Odimma enter cancer therapy clinical material supply agreement

The dbDNA vector technology of Touchlight will be used to support the immunotherapy cancer treatment candidate development.

How smart manufacturing is optimising processes and reducing costs in the pharma supply chain

Tom Lenaerts, head of global process engineering for Datwyler, speaks about smart manufacturing benefits in the pharma supply chain.

Kite and Daiichi Sankyo update cell therapy licensing agreement

According to the revised deal, the companies will transfer the marketing authorisation for Yescarta to Gilead’s Japan subsidiary.

Chemical synthesis: containment challenges for HPAPI handling

Free Webinar Solutions for Handling Nanogram Level Potent Products to Pass Containment Testing Criteria Webinar In this webinar, ILC Dover…

Health Canada approves Novavax’s Covid-19 vaccine for adolescents

The approval was based on findings from the paediatric expansion of the Phase III PREVENT-19 trial of Nuvaxovid.

GSK, Sanofi, Takeda and scientists in Singapore partner for biologics

BioPIPS intends to equip biologics production expertise in Singapore for launching new products and manufacturing technologies.

MHRA warns of serious eye-related adverse events after Dupixent use

GlobalData expects the update to raise physician and regulator vigilance over long-term Dupixent use but not impact prescription.

Pfizer and Clear Creek Bio to develop PLpro inhibitors for Covid-19

Under the agreement, Pfizer will make an undisclosed upfront payment to Clear Creek Bio.

Alzheimer’s disease biomarkers galvanise rocky drug development space

At CTAD 2022, several studies on biomarkers offered the opportunity to improve the scope of clinical research for dementia.

AbbVie and HotSpot sign partnership for autoimmune disease therapy

HotSpot is also entitled to get option fees and research and development milestone payments totalling up to $295m.

Monoclonal antibodies challenge marketed small-molecule Alzheimer’s dominance

Only 22% of all Alzheimer’s therapy approvals have been for biologics, with monoclonal antibodies accounting for 11% of these.

The rising importance of containment in small molecule drug development

With the trend for containment on the rise, we spoke to Bruno Villa, CEO, MEDELPHARM, to find out how pharmaceutical companies can protect operators working in early-stage development.

Evaxion and ExpreS²ion partner to develop new CMV vaccine

ExpreS2ion will hold the right to license the CMV vaccine under a possible development and commercialisation agreement.

MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan

Based on findings from the MIRAGE and TIDAL trials, Kyowa Kirin will seek marketing authorisation in Japan.

Managing drug shortages: Getting medicines to patients in need

Patients around the world are experiencing drug shortages, with production still recovering from the disruption caused by Covid-19, the war in Ukraine, and rising energy costs. Tanner Pharma is tackling these issues head-on, managing disruptions and ensuring that a range of treatments reach patients wherever they are.